meta|Evidence - COVID-19
click on circles to display study description...
anakinra (n=412) vs. placebo (n=194)
randomized controlled trial low risk of bias
100 mg anakinra once daily for 10 days
placebo
COVID 19 hospitalized
double-blind
12 patients withdrew consent and requested removal of alldata
anakinra (n=59) vs. control (n=57)
randomized controlled trial some concerns about risk of bias
usual care plus anakinra (200 mg twice a day on days 1–3, 100 mg twice on day 4, 100 mg once on day 5)
usual care alone
COVID-19 mild to moderate
patients with mild-to-moderate COVID-19 pneumonia, severe acute respiratory syndrome coronavirus 2 infection confirmed by real-time RT-PCR, requiring at least 3 L/min of oxygen by mask or nasal cannula but without ventilation assistance, a score of 5 on the WHO Clinical Progression Scale (WHO-CPS), and a C-reactive protein serum concentration of more than 25 mg/L not requiring admission to the intensive care unit at admission to hospital
open-label
16 university hospitals in France
powered by vis.js Network